-

12:53:17 PM

VERA Stock News

VERA - Vera Therapeutics Inc

02/27/23 4:05 PM

Nasdaq : VERA

conferenceslow float

Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team

RHEA-AI

neutral

02/06/23 4:05 PM

Nasdaq : VERA

offeringlow float

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Vera Therapeutics, Inc. (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its

RHEA-AI

neutral

02/01/23 9:51 PM

Nasdaq : VERA

offeringlow float

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics, Inc., (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its

RHEA-AI

neutral

02/01/23 4:01 PM

Nasdaq : VERA

offeringlow float

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced a public offering,

RHEA-AI

neutral

01/30/23 6:00 AM

Nasdaq : VERA

clinical triallow float

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending

RHEA-AI

neutral

01/26/23 8:00 AM

Nasdaq : VERA

managementlow float

Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer

Innocoll Holdings Ltd., a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital, today announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer.

RHEA-AI

very positive

01/25/23 8:00 AM

Nasdaq : VERA

low float

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that it will host a virtual key

RHEA-AI

neutral

01/03/23 4:01 PM

Nasdaq : VERA

clinical triallow float

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36 Atacicept safety profile in IgAN patients

RHEA-AI

neutral

12/20/22 4:05 PM

Nasdaq : VERA

conferenceslow float

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team

RHEA-AI

neutral

11/22/22 7:30 AM

Nasdaq : VERA

conferenceslow float

Vera Therapeutics to Present at Upcoming Investor Conferences

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team

RHEA-AI

neutral